337 related articles for article (PubMed ID: 36172794)
1. Bacterial outer membrane vesicle-based cancer nanovaccines.
Gao X; Feng Q; Wang J; Zhao X
Cancer Biol Med; 2022 Sep; 19(9):1290-300. PubMed ID: 36172794
[TBL] [Abstract][Full Text] [Related]
2. Nanocarriers based on bacterial membrane materials for cancer vaccine delivery.
Zhao X; Zhao R; Nie G
Nat Protoc; 2022 Oct; 17(10):2240-2274. PubMed ID: 35879454
[TBL] [Abstract][Full Text] [Related]
3. Bacterial outer membrane vesicles as a platform for biomedical applications: An update.
Li M; Zhou H; Yang C; Wu Y; Zhou X; Liu H; Wang Y
J Control Release; 2020 Jul; 323():253-268. PubMed ID: 32333919
[TBL] [Abstract][Full Text] [Related]
4. Bacterial outer membrane vesicles as a candidate tumor vaccine platform.
Wang S; Guo J; Bai Y; Sun C; Wu Y; Liu Z; Liu X; Wang Y; Wang Z; Zhang Y; Hao H
Front Immunol; 2022; 13():987419. PubMed ID: 36159867
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in various bio-applications of bacteria-derived outer membrane vesicles.
Sadeghi L; Mohit E; Moallemi S; Ahmadi FM; Bolhassani A
Microb Pathog; 2023 Dec; 185():106440. PubMed ID: 37931826
[TBL] [Abstract][Full Text] [Related]
6. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
[TBL] [Abstract][Full Text] [Related]
7. Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery.
Gnopo YMD; Watkins HC; Stevenson TC; DeLisa MP; Putnam D
Adv Drug Deliv Rev; 2017 May; 114():132-142. PubMed ID: 28501509
[TBL] [Abstract][Full Text] [Related]
8. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor.
Wang S; Huang W; Li K; Yao Y; Yang X; Bai H; Sun W; Liu C; Ma Y
Int J Nanomedicine; 2017; 12():6813-6825. PubMed ID: 28979120
[TBL] [Abstract][Full Text] [Related]
9. Engineered bacterial outer membrane vesicles: a versatile bacteria-based weapon against gastrointestinal tumors.
Zheng K; Feng Y; Li L; Kong F; Gao J; Kong X
Theranostics; 2024; 14(2):761-787. PubMed ID: 38169585
[TBL] [Abstract][Full Text] [Related]
10. Nanovaccines: An effective therapeutic approach for cancer therapy.
Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
[TBL] [Abstract][Full Text] [Related]
11. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
12. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
13. Robust Immune Response Induced by
Barbosa MMF; Kanno AI; Barazzone GC; Rodriguez D; Pancakova V; Trentini M; Faquim-Mauro EL; Freitas AP; Khouri MI; Lobo-Silva J; Goncalves VM; Schenkman RPF; Tanizaki MM; Boraschi D; Malley R; Farias LP; Leite LCC
Int J Nanomedicine; 2021; 16():7153-7168. PubMed ID: 34712047
[TBL] [Abstract][Full Text] [Related]
14. Biogenetic Vesicle-Based Cancer Vaccines with Tunable Surface Potential and Immune Potency.
Qin H; Li H; Zhu J; Qin Y; Li N; Shi J; Nie G; Zhao R
Small; 2023 Oct; 19(42):e2303225. PubMed ID: 37330651
[TBL] [Abstract][Full Text] [Related]
15. Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system.
Jin M; Huo D; Sun J; Hu J; Liu S; Zhan M; Zhang BZ; Huang JD
J Nanobiotechnology; 2024 Jan; 22(1):15. PubMed ID: 38166929
[TBL] [Abstract][Full Text] [Related]
16. Outer membrane vesicles (OMVs) enabled bio-applications: A critical review.
Huang Y; Nieh MP; Chen W; Lei Y
Biotechnol Bioeng; 2022 Jan; 119(1):34-47. PubMed ID: 34698385
[TBL] [Abstract][Full Text] [Related]
17. A modular vaccine platform enabled by decoration of bacterial outer membrane vesicles with biotinylated antigens.
Weyant KB; Oloyede A; Pal S; Liao J; Jesus MR; Jaroentomeechai T; Moeller TD; Hoang-Phou S; Gilmore SF; Singh R; Pan DC; Putnam D; Locher C; de la Maza LM; Coleman MA; DeLisa MP
Nat Commun; 2023 Jan; 14(1):464. PubMed ID: 36709333
[TBL] [Abstract][Full Text] [Related]
18. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
Wang QT; Liu YX; Wang J; Wang H
ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
[TBL] [Abstract][Full Text] [Related]
19. Delivery of foreign antigens by engineered outer membrane vesicle vaccines.
Chen DJ; Osterrieder N; Metzger SM; Buckles E; Doody AM; DeLisa MP; Putnam D
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3099-104. PubMed ID: 20133740
[TBL] [Abstract][Full Text] [Related]
20. Bacterial outer membrane vesicles engineered with lipidated antigens as a platform for
Irene C; Fantappiè L; Caproni E; Zerbini F; Anesi A; Tomasi M; Zanella I; Stupia S; Prete S; Valensin S; König E; Frattini L; Gagliardi A; Isaac SJ; Grandi A; Guella G; Grandi G
Proc Natl Acad Sci U S A; 2019 Oct; 116(43):21780-21788. PubMed ID: 31591215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
